Trial Profile
Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome: an Open-label, Randomized, Controlled, Superiority Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Rituximab
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- 28 Jul 2020 Status changed from recruiting to completed.
- 10 Jun 2015 Planned End Date changed from 1 Mar 2019 to 1 May 2019, as reported by ClinicalTrials.gov record.
- 10 Jun 2015 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018, as reported by ClinicalTrials.gov record.